Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Retatrutide
LY3437943, Eli Lilly Triple Agonist
The first widely used GLP-1 receptor agonist for weight management, developed by Novo Nordisk. Predates semaglutide and tirzepatide. While largely superseded by newer agents for weight loss, it remains FDA-approved and widely prescribed, particularly for patients who tolerate it well or have established insurance coverage.
An investigational triple-agonist peptide developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials are underway, with early results showing unprecedented weight loss efficacy.
Activates GLP-1 receptors, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Requires daily injection due to a shorter half-life than semaglutide. The daily dosing schedule is both a limitation and, for some patients, a feature — easier to stop quickly if side effects occur.
Activates three metabolic hormone receptors: GLP-1 (appetite suppression, insulin secretion), GIP (enhanced insulin response, fat metabolism), and glucagon (increased energy expenditure, fat oxidation). The triple mechanism may produce greater weight loss than dual agonists.
- Weight management (FDA-approved as Saxenda)
- Type 2 diabetes (FDA-approved as Victoza)
- Cardiovascular risk reduction
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome (investigational)
- Nausea and vomiting (common, especially during titration)
- Pancreatitis risk
- Gallbladder disease
- Potential thyroid C-cell tumor risk (animal data)
- Daily injection burden vs. weekly alternatives
- Still in clinical trials — full safety profile unknown
- GI side effects (nausea, diarrhea, vomiting) reported in trials
- Not yet approved for any indication
- Long-term effects unknown
FDA-approved as Victoza (type 2 diabetes, 2010) and Saxenda (weight management, 2014). The LEADER trial demonstrated cardiovascular risk reduction in diabetic patients. Largely superseded by semaglutide and tirzepatide for new prescriptions due to superior efficacy and weekly dosing, but remains a valid option with established long-term safety data.
Currently in Phase 3 clinical trials. Phase 2 results showed up to 24% body weight loss at 48 weeks. FDA approval timeline uncertain but potentially 2027-2028.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.